NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The dashboard will serve as a single source of truth for public and PM-JAY stakeholders providing comprehensive view of scheme’s progress
The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
The rally attracted around 250 riders, including professionals and amateurs.
AstraZeneca also played a critical role in the global response to COVID-19.
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Subscribe To Our Newsletter & Stay Updated